By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Clovis Oncology 

1871 Folsom Street

Boulder  Colorado  80302  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado.

YEAR FOUNDED:

April 20, 2009

LEADERSHIP:

Founders: Patrick Mahaffy, and Erle Mast

CEO and Co-founder: Patrick Mahaffy

CMO (Medical): Lindsey Rolfe

JOBS:

Please click here for Clovis Oncology job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


PRODUCTS:

All Products


Key Statistics


Email: info@clovisoncology.com
Ownership: Public

Web Site: Clovis Oncology
Employees:
Symbol: CLVS
 









Company News
Clovis Oncology (CLVS) Announces 2016 Operating Results 2/23/2017 7:15:51 AM
Clovis Oncology (CLVS) To Announce Fourth Quarter/Year-End 2016 Financial Results And Host Webcast Conference Call On February 22 2/10/2017 6:40:21 AM
Clovis Oncology (CLVS) And Strata Oncology Announce Collaboration To Accelerate Enrollment In Rucaparib Prostate Cancer Development Program 2/1/2017 7:12:07 AM
Clovis Oncology (CLVS) Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock 1/5/2017 11:18:03 AM
Clovis Oncology (CLVS) Announces Upsizing And Pricing Of Public Offering Of Common Stock 1/4/2017 9:53:37 AM
Clovis Oncology (CLVS) Announces Proposed Offering Of Common Stock 1/3/2017 9:27:40 AM
AmerisourceBergen (ABC) Release: US Bioservices Selected By Clovis Oncology (CLVS) To Dispense RUBRACA 12/21/2016 11:20:03 AM
Clovis Oncology (CLVS) Announces FDA Accelerated Approval Of RUBRACA (Rucaparib) For The Monotherapy Treatment Of Advanced Ovarian Cancer In Women With Deleterious Germline Or Somatic BRCA Mutations... 12/20/2016 1:16:49 PM
Avella Selected By Clovis Oncology (CLVS) To Distribute RUBRACA (Rucaparib) 12/20/2016 12:38:52 PM
Clovis Oncology (CLVS) Release: FDA Grants Accelerated Approval To New Treatment For Advanced Ovarian Cancer 12/19/2016 12:11:50 PM
12345678910...
//-->